Also found in: Medical, Wikipedia.
Related to ibandronate: ibandronate sodium

ibandronate, ibandronate sodium

(USAN), ibandronic acid (INN) n ibandronato, ibandronato sódico, ácido ibandrónico (INN)
References in periodicals archive ?
Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
One-year results from the Dosing Intravenous Administration (DIVA) study, an ongoing randomized, double-blind, phase III trial, showed that rapid injections of ibandronate (Boniva) in amounts of 2 mg every 2 months or 3 mg every 3 months were more effective than the standard oral daily dose of 2.
11 Ibandronate 61 6 Opportunity and Unmet Need 63 6.
An injectable form of the bisphosphonate ibandronate (Boniva) is approved for use every 3 months for postmenopausal osteoporosis.
VIENNA -- Oral ibandronate at 150 mg once monthly showed continued impressive therapeutic efficacy in women with postmenopausal osteoporosis at the 2-year mark in the Monthly Oral Ibandronate in Ladies (MOBILE) trial, Pierre D.
11 Ibandronate 58 6 Opportunity and Unmet Need 59 6.
SAN ANTONIO -- Ibandronate seems to be easier on the kidneys than are other bisphosphonates in cancer patients who take the drugs for bone metastases, and may even help normalize renal function in patients whose kidneys declined with zoledronic acid treatment.
A once-monthly formulation of the bisphosphonate ibandronate was recently approved by the Food and Drug Administration for treating postmenopausal osteoporosis, 2 years after a daily formulation of the drug was approved but never marketed.
PHILADELPHIA -- Intermittent intravenous injections of ibandronate continue to improve bone mineral density of the spine and hip at 2 years, according to data presented at the annual meeting of the American Society for Bone and Mineral Research.
WASHINGTON -- A monthly dose of oral ibandronate is at least as safe and as effective at increasing bone mineral density as a daily dose, according to data from a study of more than 1,200 postmenopausal women with osteoporosis.
BOSTON -- Intermittent intravenous ibandronate is at least as effective as daily oral ibandronate for increasing bone mineral density and may be preferable to oral dosing in patients with esophageal disease or compliance problems.
Studies on less frequent dosing regimens, such as the once-monthly regimen for the newly approved ibandronate (Boniva), suggest they are effective and could actually improve compliance.